Transanal Total Mesorectal Excision (TaTME) for Rectal Cancer - Overview

Introduction

Transanal Total Mesorectal Excision (taTME), commonly referred to as "bottom-up" surgery, is a new minimally invasive robotic alternative to conventional surgery that is being offered to patients who have lower rectal cancer. In cases of lower rectal cancer, the primary advantage of this treatment is that it enables the surgeon to more effectively visualize and remove the tumor, all while eliminating the need for a larger incision to be made on the skin. During the TATME technique, the tumor is entirely removed, and all of the advantages that are associated with a regular laparoscopic procedure are preserved. These advantages include a faster recovery time, minimum scarring, and less pain. Most importantly, this treatment gives the surgeon the ability to be very forceful in not removing the anus, which enables patients to avoid having a colostomy (bag) that is permanent once the procedure is complete.

What Is Rectal Cancer?

Rectal cancer is a malignant tumor that develops in the cells of the rectum, which is the last part of the large intestine.

• Rectal cancer is often characterized as a malignancy that develops gradually on the inner mucosal lining of the rectum.

• The rectum is the terminal portion of the large intestine, spanning the final few inches. Rectal malignancies typically originate from clusters of abnormal cells. The process of a polyp transforming into a malignant tumor on the rectum typically takes 10 to 15 years.

• Cancer screening procedures such as colonoscopies frequently identify polyps that have the potential to develop into cancer.

• Regular screenings aimed at identifying and eliminating polyps can effectively decrease the likelihood of getting rectal cancer.

• For individuals diagnosed with rectal cancer, undergoing surgical intervention to eliminate tiny malignant tumors can potentially result in a complete resolution of the problem. Rectal cancer ranks as the third most prevalent cancer in the digestive system, following colon cancer and pancreatic cancer.

What Are the Signs or Symptoms of Conduct Transanal Total Mesorectal Excision?

Patients diagnosed with low rectal tumors are suitable candidates for transanal total mesorectal excision (taTME), particularly those who have a higher likelihood of requiring a permanent colostomy bag, such as:

• Male patients.

• Patients who are overweight or obese.

• Individuals with a constricted pelvic structure.

What Is the Condition in Which Transanal Total Mesorectal Excision Is Conducted?

Transanal mesorectal excision (TME) is recommended as a component of the surgical procedure known as low anterior resection for individuals diagnosed with adenocarcinoma in the middle and lower parts of the rectum. Currently, it is regarded as the most reliable and widely accepted method for diagnosing cancers in these areas.

What Is the Procedure for the Surgery?

• The procedure usually starts with an abdominal laparoscopic method to look inside the peritoneal cavity and see if there are any adhesions. Carcinomatosis is the widespread presence of cancer cells in the body, typically resulting from the spread of cancer from its original site to other organs or abnormalities in the pelvic anatomy, among other things.

• With one 10 mm port and three 5 mm ports, a normal 4-port technique can be used to minimize damage to the abdominal wall. This is because a larger port for the stapler is not needed.

• A common method of ligating the inferior mesenteric artery and moving the left colon is from the middle to the side.

• Standard laparoscopic instruments, like a clip applier or an improved energy device, are needed for an anterior rectal resection, but the surgeon's choice is important. Usually, the splenic flexure needs to be fully mobilized.

• The transanal time of TaTME can begin before or after the peritoneal reflection incision from the belly. For very small tumors, this is done by hand under direct vision. For mid-to upper-level rectal lesions, an endoscopic platform is placed, and a purse-string suture is placed distal to the tumor. The rectal wall is cut around, and dissection continues until it reaches the peritoneal cavity.

• Once the sample is removed, coloanal anastomosis is performed, either from end to end or from side to end, using hand-sewing or staples.

What Are the Advantages of Transanal Total Mesorectal Excision in Rectal Cancer?

It provides a less intrusive alternative for patients with rectal cancer who are ineligible for laparoscopic surgery.

• The benefits of this treatment include reduced post-operative discomfort, decreased utilization of narcotics, accelerated healing, early restoration of bowel function, expedited return to work, and a shorter duration of hospitalization compared to an open procedure.

• Reduces the likelihood of residual tumor presence.

• Prevention of a long-term ostomy.

Transanal complete mesorectal excision (TaTME) has several advantages over traditional colon cancer surgery:

• The surgeon can obtain a clearer visualization of the inside organs.

• The surgical instruments can be manipulated with enhanced accuracy.

• The distal margin, which refers to the healthy tissue below the tumor, can be more precisely identified.

• Decreased likelihood of the disease returning due to a more thorough removal of the cancerous cells.

• Reduced duration of hospitalization.

• Accelerated surgical recovery.

What Are the Potential Risks and Complications?

Transanal Total Mesorectal Excision (TaTME) carries inherent risks and potential complications.

Transanal complete mesorectal excision (TaTME) is a more intricate surgery in comparison to typical colectomy surgeries, which involve the removal of the colon. It could be linked to the subsequent hazards:

• Anastomotic leakage occurs at the site where the colon and anus are surgically reconnected.

• Complications that can occur after surgery include post-operative bleeding

• Infection.

• Injury to the underlying blood vessels.

What Is Post-operative Care for the Patient?

Post-operative management should be similar to that of a patient undergoing a routine low anterior resection and adhere to the hospital's protocol. It is highly recommended that feeding and mobilization begin early. Before the patient's release, the abdominal closed-suction drain is removed. After surgery, the diverting stoma is closed at least three months later or sooner if adjuvant chemotherapy is administered.

Conclusion

Transanal Total Mesorectal Excision (TME) is a viable technique for surgically removing locally advanced mid- and distal-rectal cancer to cure the patient. The intraoperative outcomes related to conversion, surgery duration, and intraoperative complications are highly satisfactory. The short-term morbidity and oncologic results are comparable to those observed in prior laparoscopic total mesorectal excision (TME) studies. TaTME will inevitably continue to be developed and used in the treatment of rectal cancer. This is due to the clear reasoning behind starting the most challenging portion of the procedure early—transanal- to ensure the best possible distal margin. Furthermore, TaTME is not just used in rectal cancer surgery. This innovative "bottom-up" method is readily adaptable to other types of disease. However, new surgeons should be cautioned about the dangers of assuming this difficult method alone due to the diverse outcomes of this surgical treatment.